Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Dec 24;300(3):L486–L497. doi: 10.1152/ajplung.00237.2010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 the American Physiological Society

PMC Copyright notice

Fig. 1. — Inhibitory effects of serotonin transporter (SERT) pharmacological antagonists on PDGF-induced cell proliferation in human (H-) and bovine (B-) pulmonary artery smooth muscle cells (PASMCs). A: PDGF-induced BPASMC proliferation is inhibited by an antagonist of SERT (10 μM fluoxetine) and PDGF receptor (PDGFR) (1 μM imitinib), but not by 5-HTR2A (5 μM ketanserin) or 5-HTR1B (5 μM GR55562) antagonists. B: dose-dependent inhibitory effects of SERT antagonists (fluoxetine, imipramine, citalopram, and paroxetine) on cell proliferation by PDGF in HPASMCs and BPASMCs. C: synergistic/additive inhibition of PDGF-stimulated PASMC proliferation with combinations of SERT and PDGFR inhibitors. Representative graphs are shown as means ± SD, n = 3. *Significant difference from the untreated controls at P < 0.05. #Significant difference from cells treated with PDGF alone at P < 0.05. **Significant difference from cells treated with inhibitor alone plus PDGF at corresponding concentrations at P < 0.05.

Fig. 1. — Inhibitory effects of serotonin transporter (SERT) pharmacological antagonists on PDGF-induced cell proliferation in human (H-) and bovine (B-) pulmonary artery smooth muscle cells (PASMCs). A: PDGF-induced BPASMC proliferation is inhibited by an antagonist of SERT (10 μM fluoxetine) and PDGF receptor (PDGFR) (1 μM imitinib), but not by 5-HTR2A (5 μM ketanserin) or 5-HTR1B (5 μM GR55562) antagonists. B: dose-dependent inhibitory effects of SERT antagonists (fluoxetine, imipramine, citalopram, and paroxetine) on cell proliferation by PDGF in HPASMCs and BPASMCs. C: synergistic/additive inhibition of PDGF-stimulated PASMC proliferation with combinations of SERT and PDGFR inhibitors. Representative graphs are shown as means ± SD, n = 3. *Significant difference from the untreated controls at P < 0.05. #Significant difference from cells treated with PDGF alone at P < 0.05. **Significant difference from cells treated with inhibitor alone plus PDGF at corresponding concentrations at P < 0.05.